The GLP-1 Trap: Off, On, Repeat

White pills and syringes arranged on a reflective surface

Most people who quit Ozempic or similar drugs gain the weight back — and then go right back on the drug.

Story Snapshot

A large study of 125,474 patients found that most people stop glucagon-like peptide-1 receptor agonist (GLP-1) drugs within one year of starting them.
People taking GLP-1s for weight loss alone quit at far higher rates than those with type 2 diabetes — 65% versus 46% within the first year.
Nausea, vomiting, and cost are the top reasons people stop — but weight regain drives many right back to the pharmacy.
Only about one-third to one-half of those who quit restart within a year, and the gap is wider for people without diabetes.

Most Patients Quit Within 12 Months — The Numbers Are Stark

Ozempic and Wegovy are household names now. Millions of Americans have started them. But a major real-world study published in JAMA Network Open tracked 125,474 patients and found something the drug ads don’t mention: most people stop taking these medications before the first year is even up. Among people using GLP-1 drugs for weight loss without type 2 diabetes, 64.8% had quit within 12 months. Among those with type 2 diabetes, 46.5% had stopped. ^[5] That is not a small number. That is the majority.

The pattern holds across multiple independent studies. A British Medical Journal analysis found the median time to stopping was just 426 days — barely over a year. ^[6] A separate review found real-world discontinuation rates running between 20% and 50% in the first year alone, depending on the study population. ^[18] These are not outliers. This is what happens when a clinical-trial drug meets real life.

Why People Stop: Nausea Tops the List, Cost Comes Second

When patients explain why they quit, the answers are consistent. In one survey study, 64.4% of people who stopped said the drug “made me feel sick,” and 45.4% said it made them vomit. ^[7] Those are the top two reasons — not cost, not inconvenience, but feeling genuinely awful. A separate real-world analysis found that side effects drove 28.2% of all discontinuations across the full patient population, with cost accounting for another 12.8%. ^[8] Gastrointestinal problems are not a rare side effect with these drugs. They are the norm.

Cost and insurance coverage play a major role too — especially for people without type 2 diabetes. Insurance plans have historically covered GLP-1 drugs for diabetes management but not for obesity alone. That coverage gap hits lower-income patients hardest. Among type 2 diabetes patients earning over $80,000 a year, the likelihood of staying on the drug was 28% higher than for those earning under $30,000. ^[15] The drug works better for people who can afford to stay on it. That is not a medical finding — that is an access problem.

Weight Regain Is the Engine That Drives People Back

Here is where the story gets interesting. Many people who quit do not stay quit. Among patients with type 2 diabetes who stopped, 47.3% restarted within a year. For those without diabetes, the number was lower — 36.3% restarted. ^[10] The data shows exactly what is pulling them back. Every 1% of weight gained after stopping was linked to a 2.3% higher chance of restarting for diabetes patients and a 2.8% higher chance for those without diabetes. ^[5] The body regains weight. The patient restarts the drug. The cycle repeats.

More than half of those who stop GLP-1s restart within a year

People prescribed GLP-1 medications are more likely to start-and-stop than most people assume, according to a study being presented Sunday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, Ill.

“Our… pic.twitter.com/dXmo720zof

— Benjamin Ryan (@benryanwriter) June 14, 2026

This stop-and-restart pattern is not unique to GLP-1 drugs. It mirrors what researchers have seen for decades with other chronic medications — antidepressants, blood pressure drugs, cholesterol medications. People feel better, stop taking the drug, feel worse, and start again. The difference here is that the weight comes back fast, and with it, the health risks the drug was meant to address. One Cleveland Clinic study found that patients who stayed on the drug for a full year lost an average of 11.9% of their body weight. Those who quit within three months lost only 3.6%. ^[17] Staying on the drug matters enormously.

The Bigger Problem No One Wants to Say Out Loud

These drugs are being marketed as a revolution in obesity treatment. The clinical trials back that up — for people who stay on them at full doses. But real-world data tells a harder story. Only 14% of Wegovy patients are still taking the drug after three years. ^[16] That number should be on the label. Long-term cardiovascular benefits, which are real and documented, require long-term use. Stopping early does not just slow the results — it may erase them entirely. The drug is only as good as the patient’s ability to tolerate it, afford it, and access it consistently.

The researchers who ran the largest study put it plainly: inequities in access and adherence have the potential to make obesity disparities worse, not better. ^[3] That is a serious warning. A drug that works brilliantly for high-income patients with insurance but fails lower-income patients without diabetes coverage is not solving the obesity crisis. It is sorting people by zip code. That should concern anyone who believes in personal accountability and equal access to effective treatment — because right now, the system is not delivering either.